The cheap number is a microdose
Noom's advertised GLP-1 figure belongs to a program it calls a microdose program. It covers compounded semaglutide or compounded tirzepatide at a lower dose than the usual escalation.
That is a different product from a full-dose plan, and it is not interchangeable with one on a price table. A flat-rate seller charging more per month may be selling you a considerably larger dose.
Noom is upfront about the name. The risk is a reader who sees the figure, recognizes the brand and assumes it buys the same thing as everyone else's headline. Ask what dose you are being prescribed before you compare.
Two figures, and the second one is the one you live with
Noom publishes the intro rate and the follow-on rate in the same place. The intro covers a short starter subscription plus four weeks of medication. After that a higher monthly rate applies on a longer subscription.
Printing both together is genuinely good practice. Several sellers in this comparison advertise a first-month figure and leave the standing rate to be discovered later.
Budget on the second number. The intro rate is a few weeks of your life; the follow-on rate is the program.
The brand-name path is a fee, not a drug price
Noom also runs a brand-name route with its own figure. Its wording puts the out-of-pocket cost of the medication itself on top, depending on your insurance coverage.
So that number is the price of Noom's involvement, not the price of a GLP-1. There is nothing wrong with the structure, and Noom states it plainly.
The mistake is comparing it against a compounded figure that includes medication. Those are not the same kind of number, and the gap between them is not a saving.
You can ask for the batch paperwork
Noom tells patients they can request a certificate of analysis for their batch of compounded medication by emailing its care team. That is unusual in this field.
A certificate of analysis is the pharmacy's own testing record for the lot in your box: potency, purity, sterility. It is the document that turns a claim about quality into something you can read.
Noom still does not name the compounding pharmacy, saying only that it uses USP-compliant, state-regulated pharmacies. A batch document on request is not the same as a named pharmacy, but it is more than most sellers here will hand you.
The prices are in a drawer and the state list does not exist
Nothing on the visible Noom Med page names a figure. The prices live inside a collapsed FAQ, which means a reader scanning the page sees a program and no cost.
The intake asks around 30 questions and then wants an email address before it will show a result. Between the collapsed FAQ and the gated intake, the price is available but not offered.
Noom states in a footnote that the microdose program is not available in all 50 states, and does not say which states are excluded. Saying so at all is better than silence. Confirm your own state directly.
Noom Med's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $79/moNoom Microdose GLP-1Rx Program, "Limited Time Offer: Plans start at $79 and include medication" - covers compounded semaglutide; the footnote reads "Initial 3 week subscription and 4 weeks of medication from $79 plus tax" | September 2026source |
| Tirzepatide (compounded) | $79/moNoom Microdose GLP-1Rx Program, "Limited Time Offer: Plans start at $79 and include medication" - covers compounded tirzepatide; same starting figure as the semaglutide microdose | September 2026source |
| Semaglutide (compounded) | $179/mothe ongoing microdose rate after the intro period - "$179 per month plus tax for 12 week subscription thereafter", medication included if prescribed | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 38 providers reviewed here are paid partners today; the other 34 are not. See how this works.
See Noom Med's current price →Good fit if
- Readers who want a lower-dose GLP-1 program and know that is what they are buying.
- Patients who want the intro rate and the ongoing rate published together rather than discovering the second one in month two.
- People who want to be able to request the testing record for their own batch of compounded medication.
- Readers who want a compounded and a brand-name route offered by the same company, with the difference in scope stated.
Look elsewhere if
- Anyone who wants a standard-dose GLP-1 at the advertised figure. Noom's headline buys a microdose program.
- Readers who will not answer around 30 intake questions and give an email address to see a price. Belle Health and WeightCare publish figures on public product pages.
- Patients whose state availability matters. WeightCare publishes the states it excludes and Measured publishes the 26 it serves; Noom publishes neither.
- Anyone who needs the compounding pharmacy named. Willow names five partner pharmacies with street addresses.
How this review was verified
- Read Noom's microdose program page at its source URL and logged the intro figure and the ongoing figure with the date each was read.
- Carried the microdose scope into every qualifier, so the figure cannot travel into a comparison table as if it were a full-dose price.
- Read the footnote behind the intro figure, which sets out the starter subscription length and the four weeks of medication it covers.
- Read Noom's brand-name page separately and recorded that its figure is a program fee excluding the medication, in Noom's own words.
- Checked Noom's public GLP-1 transparency page for how it describes its pharmacies and what it offers patients, including the certificate of analysis on request.
- Confirmed that the prices on the main Noom Med page appear only after expanding a collapsed FAQ, and that the footnote stating limited state availability names no states.